Vimian Group
21.12.2021 19:53:18 CET | ACCESS Newswire | Press release
STOCKHOLM, SWEDEN / ACCESSWIRE / December 21, 2021 / Vimian Group (STO:VIMIAN)
Vimian Group has today acquired IMEX, an orthopedic implants company in Texas, United States. IMEX has revenues of around USD 2.3 million on an annual basis.
Vimian's MedTech segment Movora has today acquired IMEX. IMEX is a family-owned supplier of orthopedic implants for the veterinary market. The company was founded by Hall Griffin, Doctor of Veterinary Medicine, in 1990 and is based in Texas, US. Today, IMEX has 17 employees and is a market leader within the niche of external fixation.
"Through the acquisition of IMEX we enter a new niche segment within surgical products and complement our existing product portfolio in Movora. IMEX has a strong reputation in the veterinary market with its high-quality product brands and long-term stakeholder relationships. I have known Dr. Hall Griffin for 30 years and I am excited to now work together with him and his team", says Chris Sidebotham, Co-CEO of Vimian's MedTech segment Movora.
The acquisition will have a marginal impact on Vimian Group's earnings per share. The acquisition is financed with available funds as well as an issue in kind, resolved by the Board of Vimian based on the authorization granted by the Annual General Meeting of 2021, of a total of 110,940 shares, comprising of 55,470 ordinary shares and 55,470 class C shares, to Dr. Hall Griffin as a reinvestment in Vimian Group. The total number of shares in Vimian Group following the acquisition will amount to 389,321,230 of which 364,445,155 ordinary shares and 24,876,075 class C shares. IMEX was consolidated into Vimian Group's MedTech segment today.
For further information, please contact:
Maria Dahllöf Tullberg
Head of IR & Communications
maria.tullberg@vimian.com
+46 736 26 88 86
About Vimian
Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers' needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family - together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +150 markets, employ more than 450 people and have a combined annual turnover of approximately EUR 140 million. FNCA Sweden AB is appointed the Company's Certified Adviser, info@fnca.se, +46 (0) 8-528 00 399. For more information, please visit: www.vimian.com.
SOURCE: Vimian Group
View source version on accesswire.com:
https://www.accesswire.com/678966/Vimian-Group-Acquires-Orthopedic-Implants-Company-in-the-US
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics16.9.2026 13:00:00 CEST | Press release
Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplantation and oncology Union of two companies brings together Santersus' NucleoCapture® technology, designed to physically remove NETs from circulation, with Xenetic's DNase technology, designed to enzymatically degrade NETs in tissue Joint pipeline includes four first-in-class programs, including pivotal-stage programs in sepsis and systemic lupus erythematosus (SLE), both of which have received FDA Breakthrough Device Designation Companies to host Business Update Conference Call and Webcast Today, Wednesday, September 16th at 8:30 AM ET FRAMINGHAM, MA / ACCESS Newswire / September 16, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company advancing its Deoxyribonuclease ("DNase") technology, and Santersus AG ("Santersus"), a privately held
DataTracks Completes First Live GloBE Filing Cycle, Delivering Close to 500 Pillar Two Filings Across 10+ Jurisdictions16.9.2026 11:15:00 CEST | Press release
HMRC-authorised provider completes close to 500 Pillar Two filings, including more than 150 GIRs, for 160+ clients across 10+ jurisdictions WEYBRIDGE, GB / ACCESS Newswire / September 16, 2026 / DataTracks, recognised by HMRC as an authorised software provider supporting UK Pillar Two submissions, has completed its first live BEPS Pillar Two filing cycle, delivering close to 500 filings, including more than 150 GIRs, across 10+ jurisdictions for more than 160 clients. The milestone caps two decades of work in regulatory reporting. The cycle spanned GloBE Information Returns (GIR), domestic top-up tax returns under local QDMTT (Qualified Domestic Minimum Top-up Tax) regimes, UK Overseas Return Notifications (ORNs), and other jurisdiction-specific returns and notifications. Several jurisdictions in this cycle, including the Netherlands and Luxembourg, require similar notifications confirming where the GIR was filed centrally, under their own local terms. DataTracks filed each return dire
Hydrosat Unveils Osiris Constellation, The Future of Thermal Intelligence16.9.2026 08:00:00 CEST | Press release
Next-generation satellite constellation will combine high-resolution thermal imaging with broad-area coverage and daily revisit to support governments, businesses, and researchers worldwide. PARIS, FR / ACCESS Newswire / September 16, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, today announced Osiris, its next-generation Earth observation constellation designed to deliver wide-area, high resolution intelligence for water and food security, critical infrastructure, and national security missions. At the core of each Osiris satellite is Hydrosat's next-generation thermal infrared payload, developed to collect high-resolution thermal data across exceptionally wide areas. Operating across three longwave infrared bands, the payload will capture imagery at 25-meter native resolution over 160-kilometer to 340-kilometer swath widths, addressing one of Earth observation's biggest challenges between spatial detail and collection scale. This
Innodata Appoints Admiral Michael S. Rogers, Former NSA Director and Commander of U.S. Cyber Command, to Its Board of Directors15.9.2026 16:35:00 CEST | Press release
One of the nation's most senior cyber and intelligence leaders will help guide Innodata's strategy as it accelerates Federal and cyber-related AI initiatives. NEW YORK, NY / ACCESS Newswire / September 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced the appointment of Admiral Michael S. Rogers, U.S. Navy (Retired) - the former Director of the National Security Agency (NSA) and Commander of U.S. Cyber Command - to its Board of Directors, effective immediately. One of the highest-ranking cyber and intelligence leaders ever to serve the United States, Admiral Rogers joins at a pivotal moment, as the AI industry, enterprises and the Federal government alike wrestle with how to make increasingly capable AI systems safe and secure - and as Innodata accelerates its Federal practice launched last Fall and launches new capabilities designed specifically to make AI systems demonstrably safe and secure. "There is no one better positioned to help guide this chapter of Innodata's growth than
MicroVision Showcases Expanding Perception Portfolio at IAA Transportation 202615.9.2026 15:20:00 CEST | Press release
New Perception Platform, next-generation MOVIA S, HALO, FMCW technology, and commercial vehicle concept demonstrate MicroVision's Lidar 2.0 strategy in action REDMOND, WA AND HANOVER, GER / ACCESS Newswire / September 15, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception technologies, is showcasing the expanding breadth of its sensing and perception portfolio this week at IAA Transportation 2026, demonstrating how lidar hardware, perception software, and open sensor integration can work together to address increasingly complex applications across transportation and autonomy. At the center of MicroVision's IAA presence is the newly introduced MicroVision Perception Platform™, a flexible, modular architecture designed to allow sensing and perception configurations to be tailored to the requirements of individual applications. Throughout IAA, MicroVision is bringing that strategy to life through a series of technology demonstrations and reference concepts spanning pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom